PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Although the underlying mechanisms of DHM in the prevention and treatment of NAFLD are complex, our findings indicate that DHM improves hepatic steatosis and IR via AMPK/PGC-1α or PPARα-inducing autophagy in a rat model and steatotic hepatocytes (Fig. 9).